Brokers Offer Predictions for CRSP FY2029 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $63.56 for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the company earned ($1.41) earnings per share.

CRSP has been the subject of a number of other reports. Barclays reduced their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. JMP Securities restated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $78.38.

CRISPR Therapeutics Stock Down 1.2 %

Shares of CRSP opened at $41.92 on Wednesday. CRISPR Therapeutics has a 12 month low of $38.20 and a 12 month high of $91.10. The company’s fifty day moving average is $46.63 and its 200-day moving average is $48.94. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -14.81 and a beta of 1.68.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its stake in shares of CRISPR Therapeutics by 4.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 78,692 shares of the company’s stock valued at $4,250,000 after buying an additional 3,378 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of CRISPR Therapeutics by 14.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 61,559 shares of the company’s stock worth $3,325,000 after acquiring an additional 7,560 shares during the last quarter. Natixis Advisors LLC lifted its holdings in shares of CRISPR Therapeutics by 3.8% in the second quarter. Natixis Advisors LLC now owns 10,906 shares of the company’s stock valued at $589,000 after purchasing an additional 400 shares in the last quarter. Larson Financial Group LLC grew its position in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares in the last quarter. Finally, National Bank of Canada FI increased its position in shares of CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 1.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock worth $2,744,179 over the last three months. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.